What is ATUM?
ATUM operates at the forefront of synthetic biology, providing an integrated suite of tools for gene design, optimization, synthesis, and expression vectors. The company's platforms are engineered for protein and cellular engineering and production, leveraging the critical relationship between biological activity and sequence design. ATUM's solutions are instrumental in transforming biology from a purely discovery-based science into a robust engineering discipline, enabling clients to accelerate breakthroughs and advance research at an unprecedented pace.
How much funding has ATUM raised?
ATUM has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in ATUM
PPP
Public-Private Partnership
What's next for ATUM?
With a recent major strategic investment and substantial enterprise-level funding, ATUM is well-positioned for accelerated growth and innovation. The company's focus on engineering biology suggests a trajectory towards expanding its platform capabilities and market reach. Future developments are likely to involve deeper integration of its tools into biopharmaceutical R&D, potentially leading to new therapeutic discoveries and advanced manufacturing processes. This strategic financing will likely fuel further research and development, solidifying ATUM's position as a leader in the burgeoning field of synthetic biology and bioengineering.
See full ATUM company page
